ReviewDrug design, development and therapy2015
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
Niklas Krupka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it